Cisplatin superior to cetuximab for HPV oropharyngeal cancer
Cisplatin superior to cetuximab for HPV oropharyngeal cancer
Cisplatin v cetuximab for HPV associated oropharyngeal cancer
KEYNOTE048: First line pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma
ESMO 2018: Highlights
The promise of immunotherapy in head and neck, and prostate cancer
MyPathway study: a novel precision oncology multiple basket trial
Editor's Choice for June 2018
Novel fusion proteins to target PD-L1 in HPV associated cancers
Phase I study results of M7824 for patients with HPV associated cancers
Comment: Aspirin with acid-reducing medicine reduces chance of oesophageal cancer in high risk individuals
Maintenance chemotherapy extends life for children with rare rhabdomyosarcoma
Comment: Paediatric rhabdomyosarcoma survival extended with maintenance chemotherapy